Cookson Peirce & Co’s Amicus Therapeutics FOLD Stock Holding History

Cookson Peirce & Co’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-63,058	Closed	-$767K	–	224
2023 Q3	$767K	Buy	+63,058	New	+$813K	0.05%	118

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cookson Peirce & Co's FOLD Position: Q4 2023 in Review

Cookson Peirce & Co sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 63,058 shares — an estimated $767K sold.

Cookson Peirce & Co first reported a position in FOLD in Q3 2023 and held it in 1 quarter. The position peaked at $767K in Q3 2023. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

Cookson Peirce & Co reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
Cookson Peirce & Co sold 63,058 Amicus Therapeutics shares in Q4 2023, an estimated $767K.
Cookson Peirce & Co first reported a position in Amicus Therapeutics in Q3 2023 and held it in 1 quarter.
Cookson Peirce & Co's Amicus Therapeutics position peaked at $767K in Q3 2023.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on Cookson Peirce & Co's 13F filing for Q4 2023, filed 30 Jan 2024.